Perrigo Company plc (0Y5E.L)
USD 26.02
(-4.23%)
USD 26.02
(-4.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 10.8 Billion USD | -1.89% |
| 2022 | 11.01 Billion USD | 5.67% |
| 2021 | 10.42 Billion USD | -9.25% |
| 2020 | 11.48 Billion USD | 1.65% |
| 2019 | 11.3 Billion USD | 2.9% |
| 2018 | 10.98 Billion USD | -5.55% |
| 2017 | 11.62 Billion USD | -16.16% |
| 2016 | 13.87 Billion USD | -29.67% |
| 2015 | 19.72 Billion USD | 42.08% |
| 2014 | 13.88 Billion USD | 159.4% |
| 2013 | 5.35 Billion USD | 32.97% |
| 2012 | 4.02 Billion USD | 26.18% |
| 2011 | 3.18 Billion USD | 3.12% |
| 2010 | 3.09 Billion USD | 21.94% |
| 2009 | 2.53 Billion USD | -1.5% |
| 2008 | 2.57 Billion USD | 33.76% |
| 2007 | 1.92 Billion USD | 9.97% |
| 2006 | 1.75 Billion USD | 2.68% |
| 2005 | 1.7 Billion USD | 124.61% |
| 2004 | 759.09 Million USD | 17.88% |
| 2003 | 643.97 Million USD | 8.45% |
| 2002 | 593.78 Million USD | 3.1% |
| 2001 | 575.91 Million USD | 18.48% |
| 2000 | 486.06 Million USD | -21.08% |
| 1999 | 615.9 Million USD | 3.36% |
| 1998 | 595.9 Million USD | 4.84% |
| 1997 | 568.4 Million USD | 3.46% |
| 1996 | 549.4 Million USD | -1.13% |
| 1995 | 555.7 Million USD | 16.99% |
| 1994 | 475 Million USD | 14.82% |
| 1993 | 413.7 Million USD | 30.55% |
| 1992 | 316.9 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.64 Billion USD | -1.56% |
| 2024 Q2 | 10.39 Billion USD | -2.28% |
| 2023 Q1 | 10.95 Billion USD | -0.57% |
| 2023 FY | 10.8 Billion USD | -1.89% |
| 2023 Q3 | 10.75 Billion USD | -1.88% |
| 2023 Q2 | 10.96 Billion USD | 0.09% |
| 2023 Q4 | 10.8 Billion USD | 0.47% |
| 2022 FY | 11.01 Billion USD | 5.67% |
| 2022 Q3 | 10.67 Billion USD | -2.22% |
| 2022 Q2 | 10.91 Billion USD | 5.1% |
| 2022 Q1 | 10.38 Billion USD | -0.35% |
| 2022 Q4 | 11.01 Billion USD | 3.18% |
| 2021 Q3 | 10.91 Billion USD | -2.8% |
| 2021 Q1 | 11.32 Billion USD | -1.42% |
| 2021 Q4 | 10.42 Billion USD | -4.49% |
| 2021 FY | 10.42 Billion USD | -9.25% |
| 2021 Q2 | 11.23 Billion USD | -0.83% |
| 2020 Q1 | 11.4 Billion USD | 0.88% |
| 2020 Q2 | 12.12 Billion USD | 6.38% |
| 2020 Q4 | 11.48 Billion USD | -0.76% |
| 2020 Q3 | 11.57 Billion USD | -4.55% |
| 2020 FY | 11.48 Billion USD | 1.65% |
| 2019 Q4 | 11.3 Billion USD | -0.08% |
| 2019 Q2 | 11.42 Billion USD | 2.78% |
| 2019 Q1 | 11.11 Billion USD | 1.24% |
| 2019 FY | 11.3 Billion USD | 2.9% |
| 2019 Q3 | 11.31 Billion USD | -1.03% |
| 2018 Q3 | 10.94 Billion USD | -2.52% |
| 2018 Q2 | 11.22 Billion USD | -3.56% |
| 2018 Q4 | 10.98 Billion USD | 0.37% |
| 2018 Q1 | 11.63 Billion USD | 0.09% |
| 2018 FY | 10.98 Billion USD | -5.55% |
| 2017 Q1 | 13.97 Billion USD | 0.79% |
| 2017 FY | 11.62 Billion USD | -16.16% |
| 2017 Q4 | 11.62 Billion USD | -1.81% |
| 2017 Q3 | 11.84 Billion USD | 0.43% |
| 2017 Q2 | 11.79 Billion USD | -15.65% |
| 2016 Q2 | 19.53 Billion USD | -1.09% |
| 2016 Q3 | 17.46 Billion USD | -10.58% |
| 2016 Q4 | 13.87 Billion USD | -20.6% |
| 2016 FY | 13.87 Billion USD | -29.67% |
| 2016 Q1 | 19.74 Billion USD | 1.83% |
| 2015 FY | 19.72 Billion USD | 42.08% |
| 2015 Q3 | 19.7 Billion USD | -0.09% |
| 2015 Q4 | 19.39 Billion USD | -1.57% |
| 2015 Q2 | 19.72 Billion USD | 21.86% |
| 2015 Q1 | 16.18 Billion USD | -1.69% |
| 2014 FY | 13.88 Billion USD | 159.4% |
| 2014 Q2 | 13.88 Billion USD | 1.0% |
| 2014 Q4 | 16.46 Billion USD | 19.44% |
| 2014 Q3 | 13.78 Billion USD | -0.71% |
| 2014 Q1 | 13.74 Billion USD | 0.22% |
| 2013 Q1 | 4.49 Billion USD | 4.69% |
| 2013 FY | 5.35 Billion USD | 32.97% |
| 2013 Q4 | 13.71 Billion USD | 148.93% |
| 2013 Q3 | 5.5 Billion USD | 2.95% |
| 2013 Q2 | 5.35 Billion USD | 19.02% |
| 2012 FY | 4.02 Billion USD | 26.18% |
| 2012 Q4 | 4.29 Billion USD | 4.3% |
| 2012 Q3 | 4.11 Billion USD | 2.32% |
| 2012 Q2 | 4.02 Billion USD | -0.4% |
| 2012 Q1 | 4.04 Billion USD | 2.47% |
| 2011 Q4 | 3.94 Billion USD | 12.19% |
| 2011 Q1 | 3.03 Billion USD | 3.49% |
| 2011 Q2 | 3.18 Billion USD | 5.0% |
| 2011 Q3 | 3.51 Billion USD | 10.19% |
| 2011 FY | 3.18 Billion USD | 3.12% |
| 2010 Q4 | 2.93 Billion USD | 5.89% |
| 2010 Q2 | 3.09 Billion USD | 21.59% |
| 2010 Q1 | 2.54 Billion USD | -1.03% |
| 2010 FY | 3.09 Billion USD | 21.94% |
| 2010 Q3 | 2.77 Billion USD | -10.38% |
| 2009 Q4 | 2.57 Billion USD | 2.84% |
| 2009 Q2 | 2.53 Billion USD | 6.93% |
| 2009 Q3 | 2.49 Billion USD | -1.47% |
| 2009 Q1 | 2.37 Billion USD | -2.22% |
| 2009 FY | 2.53 Billion USD | -1.5% |
| 2008 Q1 | 2.19 Billion USD | 7.75% |
| 2008 Q3 | 2.49 Billion USD | -3.17% |
| 2008 FY | 2.57 Billion USD | 33.76% |
| 2008 Q2 | 2.57 Billion USD | 17.19% |
| 2008 Q4 | 2.42 Billion USD | -2.71% |
| 2007 Q1 | 1.89 Billion USD | 1.97% |
| 2007 FY | 1.92 Billion USD | 9.97% |
| 2007 Q2 | 1.92 Billion USD | 1.83% |
| 2007 Q3 | 1.94 Billion USD | 1.12% |
| 2007 Q4 | 2.03 Billion USD | 4.76% |
| 2006 Q4 | 1.85 Billion USD | 2.11% |
| 2006 Q3 | 1.81 Billion USD | 3.72% |
| 2006 Q2 | 1.75 Billion USD | 4.77% |
| 2006 Q1 | 1.67 Billion USD | -0.78% |
| 2006 FY | 1.75 Billion USD | 2.68% |
| 2005 Q3 | 1.69 Billion USD | -0.82% |
| 2005 Q4 | 1.68 Billion USD | -0.41% |
| 2005 Q2 | 1.7 Billion USD | -1.51% |
| 2005 Q1 | 1.73 Billion USD | 120.14% |
| 2005 FY | 1.7 Billion USD | 124.61% |
| 2004 Q2 | 759.09 Million USD | 1.67% |
| 2004 FY | 759.09 Million USD | 17.88% |
| 2004 Q3 | 762.13 Million USD | 0.4% |
| 2004 Q4 | 786.41 Million USD | 3.19% |
| 2004 Q1 | 746.64 Million USD | 5.57% |
| 2003 Q2 | 643.97 Million USD | 2.42% |
| 2003 Q3 | 650.44 Million USD | 1.01% |
| 2003 Q1 | 628.72 Million USD | 3.54% |
| 2003 FY | 643.97 Million USD | 8.45% |
| 2003 Q4 | 707.24 Million USD | 8.73% |
| 2002 Q4 | 607.23 Million USD | 1.68% |
| 2002 Q2 | 593.78 Million USD | 3.59% |
| 2002 Q1 | 573.19 Million USD | 0.73% |
| 2002 FY | 593.78 Million USD | 3.1% |
| 2002 Q3 | 597.17 Million USD | 0.57% |
| 2001 Q4 | 569.01 Million USD | -5.13% |
| 2001 Q3 | 599.81 Million USD | 4.15% |
| 2001 Q2 | 575.91 Million USD | 6.35% |
| 2001 Q1 | 541.52 Million USD | 3.94% |
| 2001 FY | 575.91 Million USD | 18.48% |
| 2000 FY | 486.06 Million USD | -21.08% |
| 2000 Q2 | 486.06 Million USD | -4.11% |
| 2000 Q1 | 506.88 Million USD | -12.86% |
| 2000 Q4 | 521.02 Million USD | -0.09% |
| 2000 Q3 | 521.49 Million USD | 7.29% |
| 1999 FY | 615.9 Million USD | 3.36% |
| 1999 Q3 | 609.5 Million USD | -1.04% |
| 1999 Q4 | 581.7 Million USD | -4.56% |
| 1999 Q2 | 615.9 Million USD | -10.04% |
| 1999 Q1 | 684.6 Million USD | -3.63% |
| 1998 Q4 | 710.4 Million USD | 12.03% |
| 1998 Q3 | 634.1 Million USD | 6.41% |
| 1998 FY | 595.9 Million USD | 4.84% |
| 1998 Q2 | 595.9 Million USD | -8.37% |
| 1998 Q1 | 650.3 Million USD | 1.42% |
| 1997 Q4 | 641.2 Million USD | 3.02% |
| 1997 FY | 568.4 Million USD | 3.46% |
| 1997 Q3 | 622.4 Million USD | 9.5% |
| 1997 Q2 | 568.4 Million USD | 0.98% |
| 1997 Q1 | 562.9 Million USD | -0.28% |
| 1996 FY | 549.4 Million USD | -1.13% |
| 1996 Q1 | 565.1 Million USD | -4.85% |
| 1996 Q2 | 549.4 Million USD | -2.78% |
| 1996 Q3 | 571.8 Million USD | 4.08% |
| 1996 Q4 | 564.5 Million USD | -1.28% |
| 1995 Q3 | 594.2 Million USD | 6.93% |
| 1995 Q2 | 555.7 Million USD | 0.96% |
| 1995 Q1 | 550.4 Million USD | 8.45% |
| 1995 FY | 555.7 Million USD | 16.99% |
| 1995 Q4 | 593.9 Million USD | -0.05% |
| 1994 Q4 | 507.5 Million USD | 0.2% |
| 1994 FY | 475 Million USD | 14.82% |
| 1994 Q1 | 463.6 Million USD | 1.98% |
| 1994 Q2 | 475 Million USD | 2.46% |
| 1994 Q3 | 506.5 Million USD | 6.63% |
| 1993 Q3 | 456.8 Million USD | 10.42% |
| 1993 FY | 413.7 Million USD | 30.55% |
| 1993 Q1 | 389.7 Million USD | 5.95% |
| 1993 Q2 | 413.7 Million USD | 6.16% |
| 1993 Q4 | 454.6 Million USD | -0.48% |
| 1992 Q3 | 346.9 Million USD | 9.47% |
| 1992 Q1 | 297.9 Million USD | 23.82% |
| 1992 FY | 316.9 Million USD | 0.0% |
| 1992 Q2 | 316.9 Million USD | 6.38% |
| 1992 Q4 | 367.8 Million USD | 6.02% |
| 1991 Q4 | 240.6 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -1199.656% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -1053.441% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -1289.559% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -6431.02% |
| bluebird bio, Inc. | 619.16 Million USD | -1645.766% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -8489.285% |
| Imunon, Inc. | 21.91 Million USD | -49215.932% |
| Editas Medicine, Inc. | 499.15 Million USD | -2065.488% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 59.488% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -222.126% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -801.735% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -232.444% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -667.159% |
| Verastem, Inc. | 149.71 Million USD | -7119.64% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 86.662% |
| Waters Corporation | 4.62 Billion USD | -133.617% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 89.051% |
| Biogen Inc. | 26.84 Billion USD | 59.735% |
| Nektar Therapeutics | 398.03 Million USD | -2615.629% |
| Dynavax Technologies Corporation | 997.09 Million USD | -984.058% |
| Illumina, Inc. | 10.11 Billion USD | -6.904% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -38131.995% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -1285.159% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -4757.891% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -16354.712% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -57.991% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -6438.289% |
| Evolus, Inc. | 188.99 Million USD | -5619.161% |
| Adicet Bio, Inc. | 207.29 Million USD | -5114.356% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -5375.596% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 67.325% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -5152.337% |
| FibroGen, Inc. | 423.52 Million USD | -2452.151% |
| Agilent Technologies, Inc. | 10.76 Billion USD | -0.428% |
| OPKO Health, Inc. | 2.01 Billion USD | -437.312% |
| Homology Medicines, Inc. | 47.05 Million USD | -22870.228% |
| Geron Corporation | 394.07 Million USD | -2642.897% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -182.231% |
| Exelixis, Inc. | 2.94 Billion USD | -267.362% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -2833.35% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -6901.347% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -730.845% |
| Zoetis Inc. | 14.28 Billion USD | 24.338% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1737.545% |
| Abeona Therapeutics Inc. | 64 Million USD | -16788.691% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 52.446% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -19219.559% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -261.5% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -231.103% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -1639.148% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -523.625% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -930.174% |
| Insmed Incorporated | 1.32 Billion USD | -712.814% |
| TG Therapeutics, Inc. | 329.58 Million USD | -3179.589% |
| Incyte Corporation | 6.78 Billion USD | -59.377% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -489.084% |